[Primary dysmenorrhea treated with sublingual piroxicam]

Area of Science:

• Pharmacology
• Gastroenterology
• Women's Health

Background:

• Primary dysmenorrhea is a common gynecological condition characterized by painful menstrual cramps.
• Effective and rapid-acting pain management is crucial for improving the quality of life for affected individuals.

Purpose of the Study:

• To evaluate the efficacy and tolerability of a new piroxicam fast dissolving dosage form (FDDF) administered sublingually for primary dysmenorrhea.
• To assess the onset of analgesic action and impact on associated symptoms and daily activities.

Main Methods:

• An open-label, non-comparative study involving 54 patients with primary dysmenorrhea.
• Patients received piroxicam FDDF tablets: 40 mg daily for two days, followed by 20 mg daily for three days, over two menstrual cycles.
• Efficacy was measured by pain intensity, associated symptoms (cephalgia, nausea, vomiting), and ability to perform daily activities.

Main Results:

• Statistically significant pain reduction (p = 0.0001) was observed within 15 minutes of administration in both cycles, with greater relief in the second cycle.
• Associated symptoms like cephalgia and low back pain significantly decreased, particularly during the second cycle.
• Good local and systemic tolerability was reported, with minimal and manageable side effects, some of which are common to dysmenorrhea itself.

Conclusions:

• Piroxicam FDDF administered sublingually provides rapid and effective pain relief for primary dysmenorrhea, with significant improvement noted within 15 minutes.
• The formulation demonstrates good tolerability and is a viable option for managing menstrual pain and associated symptoms.
• The enhanced absorption and rapid action of the sublingual fast-dissolving form contribute to its clinical effectiveness in primary dysmenorrhea treatment.